These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15853179)

  • 1. Cost considerations surrounding current and future anticoagulant therapies.
    Fang MC; Minichiello T; Auerbach AD
    Cleve Clin J Med; 2005 Apr; 72 Suppl 1():S43-9. PubMed ID: 15853179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
    Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
    Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic considerations in the prevention and treatment of venous thromboembolism.
    Hawkins D
    Am J Health Syst Pharm; 2004 Dec; 61(23 Suppl 7):S18-21. PubMed ID: 15597575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
    Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
    Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic considerations in anticoagulant drug use.
    Hawkins D; Huston SA
    Expert Opin Pharmacother; 2006 Jun; 7(8):989-1003. PubMed ID: 16722810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism.
    Aujesky D; Smith KJ; Cornuz J; Roberts MS
    Thromb Haemost; 2005 Mar; 93(3):592-9. PubMed ID: 15735815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial management of deep venous thrombosis in the outpatient setting.
    Groce JB
    Am J Health Syst Pharm; 2008 May; 65(9):866-74. PubMed ID: 18436734
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-molecular-weight heparin prophylaxis against thromboembolism after total hip replacement--the never-ending story?
    Dahl OE; Bergqvist D; Cohen AT; Frostick SP; Hull RD
    Acta Orthop Scand; 2001 Apr; 72(2):199-204. PubMed ID: 11372955
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacoeconomics of thrombosis management.
    Hawkins D
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):95S-99S. PubMed ID: 15317405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboprophylaxis with low-molecular-weight heparin: economic considerations.
    Mätzsch T
    Haemostasis; 2000; 30 Suppl 2():141-5; discussion 128-9. PubMed ID: 11251359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of venous thromboembolism using only low-molecular-weight heparin?
    White RH
    Am J Med; 2001 Aug; 111(2):159-60. PubMed ID: 11498072
    [No Abstract]   [Full Text] [Related]  

  • 14. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery.
    Bergqvist D
    Vasc Health Risk Manag; 2006; 2(4):365-70. PubMed ID: 17323590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
    Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
    Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis.
    Marchetti M; Pistorio A; Barone M; Serafini S; Barosi G
    Am J Med; 2001 Aug; 111(2):130-9. PubMed ID: 11498067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimizing costs for treating deep vein thrombosis: the role for fondaparinux.
    Shorr AF; Jackson WL; Moores LK; Warkentin TE
    J Thromb Thrombolysis; 2007 Jun; 23(3):229-36. PubMed ID: 17131172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery.
    Spruill WJ; Wade WE; Leslie RB
    Blood Coagul Fibrinolysis; 2004 Oct; 15(7):539-43. PubMed ID: 15389119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight heparin, heparin, and warfarin.
    Raskob GE
    Curr Opin Hematol; 1995 Sep; 2(5):372-9. PubMed ID: 9372022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
    Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
    Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.